07.05.2013 • News

DSM to Acquire Interest in Andre Pectin (China)

Royal DSM, the global Life Sciences and Materials Sciences company, announces today that it has signed agreements to acquire a 19% equity interest in Yantai Andre Pectin (Andre Pectin), a China based producer of texturing ingredients. In addition, the parties have agreed that DSM has option rights to increase its stake in Andre Pectin to a majority stake at a later stage.

The agreements are subject to customary approvals and certain closing conditions, including the approval of the selling party's shareholders.

Closing is expected in Q3 2013.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read